Supplementary Figures
. The surface of VHL and Brd4 BD2 is colored pale green and light blue, respectively. In (B), atomic displacements > 1.5 Å upon energyminimization are highlighted in dotted orange lines. No such large rearrangements were observed in (C), suggesting that the linker was more appropriate.
Figure S2. Structural integrity and stability of the VHL:1:Brd4 BD2 ternary complex along the MD simulation. (A) Histogram depicting the observed relative frequency of binned distances between the attachment points in compound 1. (B)
Buried surface area (BSA) in the interface of VHL with Brd4 BD2 and root-mean-square deviation (RMSD) of all α-carbon atoms in the proteins, after superposition to the crystal structure of VCB:MZ1:Brd4 BD2 (PDB code 5T35). [1] (C) Minimum distance between selected amino acids in VHL and Brd4 BD2 that participate in protein-protein interactions. [1] For clarity, the plotted distances are the average over 5 ns. In all cases, only the last 50 ns in 100 ps intervals of a 200-ns MD simulation of the VHL:1:Brd4 BD2 ternary complex were considered to generate the data. The mean ± 1 s.d. of each measurement is shown. Figure S3 . Interactions in the VHL:1:Brd4 BD2 ternary complex along the MD simulation. (A) Protein-protein and proteinligand interactions (showed in dashed yellow lines) observed at 10 ns intervals along the last 50 ns of a 200-ns MD simulation of the VHL:1:Brd4 BD2 ternary complex. A conserved water network stabilized at the interface of the three partners is shown along the simulation. In the first panel, interacting amino acids in VHL and Brd4 BD2 are labelled. (B) Superposition of the frames showed in (A), with the time lapse colored from blue to dark red. Water molecules within the network form clusters at specific locations of the interface, indicating that they engage in stabilizing interactions with their surrounding during the simulation. 
Computational methods

Torsion analysis of surrogate N-substituted acetamides
Model compounds N-ethylacetamide and N-isopropylacetamide (Fig. 1C ) were subjected to a relaxed torsion scan analysis of their alkylacetamide bond using density functional theory (DFT) at the PBF (water) MN15-L/aug-cc-pVTZ(-F) level of theory in Jaguar 9.7 (Schrödinger, LLC).
The C-N-C-C torsion was gradually rotated from 0 to 180º in 10º steps, considering Abelian molecular symmetry when appropriate.
Molecular modeling of macrocyclic MZ1 derivatives
Derivatives of MZ1 macrocyclized using a 2-PEG and a 3-PEG linker ( Fig. 1D ) were modeled in situ using the VHL:MZ1:Brd4 BD2 ternary complex crystal structure as template and Glide Ligand Designer (Schrödinger). Water and solvent molecules present in the protein crystal structure were removed, and the VHL:MZ1:Brd4 BD2 system was prepared for energy minimization in Prime (Schrödinger) using the Protein Preparation Wizard (Schrödinger). Amino acid protonation states were assigned using PROPKA 3.0. [2] 
Molecular dynamics (MD) simulation of the VHL:1:Brd4 BD2 ternary complex
The energy-minimized model of VHL:1:Brd4 BD2 was used as starting point for a molecular dynamics (MD) simulation. MD simulations were carried out in an nVIDIA TITAN X GPU using Desmond (Schrödinger) and the OPLS3 force field. [3] System Builder (Schrödinger) was used to solvate the complex in a TIP3P water box with a padding of 10 Å from the edge of the box to any solute atom, and to neutralize the system charges with three chloride ions. The solvated system was minimized for 2,000 steps with all protein and PROTAC atoms restrained to eliminate residual unfavorable interactions between the solute and the solvent, followed by another 2,000 steps with unrestrained PROTAC and solvent atoms, and lastly followed by another 5,000 steps with all atoms free to move. The equilibration phase consisted of an initial 100-ps Brownian dynamics simulation at 10 K with restraints on solute heavy atoms in the NVT ensemble, followed by one run of 120 ps of MD at the same temperature, restraints, and ensemble. The restrained system was then subjected to two runs of 120 ps in the NPT ensemble, first at 10 K and then at 300 K, and a final unrestrained simulation at the final temperature (300 K) for 240 ps. We run 200 ns of MD (time step of 2 fs using the RESPA integrator), starting from the equilibrated system. The temperature was controlled with a Nose-Hoover chain thermostat at 300 K, and the pressure with a Martyna-Tobias-Klein barostat at 1 bar. Short-range nonbonded interactions were cut off at 9 Å.
Only the last 50 ns of production simulation were used for data collection and analysis.
Analysis of MD trajectories
The last 50 ns of the 200-ns MD trajectory were analyzed using the Simulation Quality, Event, and Interactions Analysis tools, as included in Schrödinger. The buried surface area (BSA) of the proteins upon complex formation, i.e. the difference in surface-accessible surface area (SASA) between the formed complex and the unbound partners in each system, was computed using VMD v. 1.9.2 [4] and considering all protein atoms and a spherical probe of radius 1.4 Å.
System
Number of atoms 
Chemistry
All chemicals, unless otherwise stated were commercially available and used without further purification. Solvents were anhydrous and reactions preformed under positive pressure of nitrogen or argon. Enantiopure (+)-JQ-1 was purchased from Medchemexpress LLC, Princeton, USA.
Flash column chromatography (FCC) was performed using a Teledyne Isco Combiflash Rf or Preparative HPLC was performed on a Gilson Preparative HPLC System with a Waters X-Bridge C18 column (100 mm × 19 mm; 5 μm particle size). 
(S)-4-((2-(2-(benzyloxy)ethoxy)ethoxy)methyl)-2,2-dimethyl-1,3-dioxolane (5)
To a solution of (S)-(+)-1,2-isopropylideneglycerol 3 (1.6 g, 12.0 mmol) in dioxane (40 mL) freshly ground KOH (740 mg, 13.2 mmol) was added, followed by 2-(2-(benzyloxy)ethoxy)ethyl 4-methylbenzenesulfonate 4 (7.0 g, 20 mmol) and a catalytic amount of tetrabutylammonium iodide. The mixture was stirred at 105 °C overnight. The solvent was removed under reduced pressure, a saturated solution of ammonium chloride (50 mL) was added to the residue and the mixture was extracted with DCM (3 × 100 mL). The collected organic phase was dried on anhydrous MgSO4, evaporated to dryness and the crude was purified by FCC using a gradient from 10% to 50% of EtOAc in heptane. Obtained 1.94 g, 52% (transparent oil). 
¹H
(R)-3-(2-(2-(benzyloxy)ethoxy)ethoxy)propane-1,2-diol (6)
The acetonide 5 (1.94 g, 6.25 mmol) was dissolved in 80% aqueous acetic acid (40 mL) and stirred until complete consumption of the starting material was observed by TLC (50% of EtOAc in heptane). The reaction mixture was evaporated to dryness to obtain the desired product in 11-((2-(2-(2-(((2S,4R)-1-((S)-2-((tert-butoxycarbonyl) To a solution of 13 (187 mg, 0.40 mmol) in DCM (3 mL) at 0 °C, TEA (84 µL, 0.60 mmol) was added, followed by mesyl chloride (37 µL, 0.48 mmol). The reaction mixture was stirred at 0 °C for 10 min and then allowed to reach r.t. over 3 h. A 5% solution of NaHCO3 was added, the reaction mixture was extracted with DCM, the organic phase was over MgSO4 and concentrate in vacuo to give the mesylate linker which was immediately dissolved in anhydrous DMF (2 mL).
tert-butyl (S)-
Compound 15 [6] (145 mg, 0.27 mmol) was added to the mesylate solution, followed by freshly ground anhydrous K2CO3 (110 mg, 0.80 mmol). The reaction mixture was vigorously stirred at 75 °C overnight. The reaction mixture was then allowed to cool to r. 2R,6S,18S,33aS)-6-(tert-butyl)-2-hydroxy-28-(4-methylthiazol-5-yl)-5,8,33-trioxo-2,3,6,7,8,9,11,12,14,15,18,19,21,22,24,25,31,32,33,33a (2R,6S,18S,33aS)-18-amino-6-(tert-butyl)-2-hydroxy-28-(4-methylthiazol-5-yl)-1,2,3,6,7,11,12,14,15,18,19,21,22,24,25,31,32,33a-octadecahydro-5H,17H N-((2R,6S,18S,33aS)-6-(tert-butyl)-2-hydroxy-28-(4-methylthiazol-5-yl)-5,8,33-trioxo-2,3,6,7,8,9,11,12,14,15,18,19,21,22,24,25,31,32,33,33a 
4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6yl)acetamide (1)
To a solution of amine 17 (10 mg, 0.136 mmol), (+)-JQ1-COOH [7] 
Protein expression and purification
Wild 
Isothermal titration calorimetry (ITC)
The titrations were all performed as reverse mode (protein in syringe, ligand in cell) and consisted 
Fluorescence polarization assay
FP competitive binding assays were run in triplicate on 384-well plates [Corning 3575] as described previously, [8] with all measurements taken using a PHERAstar FS (BMG LABTECH) with fluorescence excitation and emission wavelengths (λ) of 485 and 520 nm, respectively. The 
Crystallography
The ternary complex VCB:1:Brd4 BD2 was prepared by combining VCB, Brd4 BD2 , and 1 in a 1:1:1 molar ratio and incubating for 15 min at RT. Crystals were grown at 20 °C using the hanging- Diffraction data were collected at Diamond Light Source beamline I04 using a Pilatus 6M-F detector at a wavelength of 0.9750 Å. Reflections were indexed and integrated using XDS [9] , and scaling and merging were performed with AIMLESS [10] in CCP4i. [11] The crystals belonged to space group P32, and there were two copies of the ternary complex in the asymmetric unit. The structure was solved by molecular replacement using PHASER MR [12] and search models derived from the coordinates for the VCB:MZ1:Brd4 BD2 ternary complex (PDB entry 5T35). The initial model underwent iterative rounds of model building and refinement with COOT [13] and REFMAC5, [14] respectively. All riding hydrogens were excluded from the output coordinate files but included for refinement. Compound 1 geometry restraints for refinement were prepared with the PRODRG [15] server and optimized using eLBOW [16] from the PHENIX suite. [17] Model geometry and steric clashes were validated using the MOLPROBITY server. [18] Ramachandran plots indicate that 96.8% of backbone torsion angles are in the favored region and there are no outliers. The structure has been deposited in the protein data bank (PDB) with accession code 6SIS; data collection and refinement statistics are presented in 
Tissue culture
HeLa cells were kept in DMEM (Gibco) supplemented with 10%(v/v) FBS (Gibco), 2 mM Lglutamine (Gibco), penicillin (100 units /mL) and streptomycin (100 μg/mL) (Gibco). Mv4;11 and 22RV1 (ATCC CRL-2505) cells were kept in RPMI 1640 supplemented with 10% (v/v) FBS (Gibco), 2 mM L-glutamine (Gibco), penicillin (100 units /mL) and streptomycin (100 μg/mL) (Gibco). Cells were kept at 37 °C, 5% CO2.
Testing compounds in cells
HeLa cells or 22RV1 cells (6 × 10 5 ) were seeded onto each well on a six-well plate 24 h before treatment with test compounds. To treat the cells with the test compounds, medium was replaced with fresh medium containing specified concentration of test compounds for either 4 h or 18 h.
The same DMSO concentration was maintained in all samples. At the end of treatment, cells were washed with PBS and then lysed in RIPA buffer (Sigma, R0278) supplemented with HALT Protease inhibitor (ThermoFisher, # 78842). Lysate was incubated on ice for 15 min and then clarified by centrifugation (20,000 × g, 10 min, 4 °C). Supernatant was collected and protein concentration was determined by BCA assay. The rest of the clarified lysate was kept at -20°C before further processing.
Immunoblotting
Protein on gel was transferred to nitrocellulose membrane using the Bio-Rad Transblot system according to manufacturer guidelines. Blots were probed with anti-Brd4 (AbCam, ab128874), anti-Brd3 (AbCam, ab50818), anti-Brd2 (AbCam, ab139690) and anti-c-MYC (Y69 ab32072) followed by hFAB™ Rhodamine Anti-Tubulin (Biorad #12004165) and anti-mouse IgG (Licor, 926-32210) or anti-rabbit IgG (Licor, 926-32213) antibodies and bands visualized using Bio-Rad ChemiDoc MP Imaging System.
Western Blot Quantification
Image processing and band intensity quantification were performed using Bio-Rad Image Lab software version 6.0.0. Reported band intensities are first normalized to tubulin loading control and then to DMSO only treated sample. 
Cell Viability Assay
